{"id":"lactulose","rwe":[],"_fda":{"id":"bda4ccaa-fa33-4911-b3bd-12391c365f47","set_id":"00c42c5c-d19e-4130-aa08-a8bbd47d3e5b","openfda":{"nui":["N0000175811","N0000010288","N0000175833","N0000009871"],"unii":["9U7D5QH5AE"],"route":["ORAL","RECTAL"],"rxcui":["391937","755470"],"spl_id":["bda4ccaa-fa33-4911-b3bd-12391c365f47"],"brand_name":["Enulose"],"spl_set_id":["00c42c5c-d19e-4130-aa08-a8bbd47d3e5b"],"package_ndc":["45963-438-64"],"product_ndc":["45963-438"],"generic_name":["LACTULOSE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Stimulation Large Intestine Fluid/Electrolyte Secretion [PE]"],"substance_name":["LACTULOSE"],"pharm_class_epc":["Osmotic Laxative [EPC]"],"pharm_class_moa":["Osmotic Activity [MoA]","Acidifying Activity [MoA]"],"manufacturer_name":["Actavis Pharma, Inc."],"application_number":["ANDA090502"],"is_original_packager":[true]},"version":"8","warnings":["WARNINGS A theoretical hazard may exist for patients being treated with lactulose solution who may be required to undergo electrocautery procedures during proctoscopy or colonoscopy. Accumulation of H 2 gas in significant concentration in the presence of an electrical spark may result in an explosive reaction. Although this complication has not been reported with lactulose, patients on lactulose therapy undergoing such procedures should have a thorough bowel cleansing with a non-fermentable solution. Insufflation of CO 2 as an additional safeguard may be pursued but is considered to be a redundant measure."],"pregnancy":["Pregnancy Teratogenic Effects Pregnancy category B . Reproduction studies have been performed in mice, rats, and rabbits at doses up to 2 or 4 times the usual human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to lactulose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."],"overdosage":["OVERDOSAGE Signs and Symptoms There have been no reports of accidental overdosage. In the event of overdosage, it is expected that diarrhea and abdominal cramps would be the major symptoms. Medication should be terminated. Oral LD 50 : The acute oral LD 50 of the drug is 48.8 mL/kg in mice and greater than 30 mL/kg in rats. Dialysis: Dialysis data are not available for lactulose. Its molecular similarity to sucrose, however, would suggest that it should be dialyzable."],"description":["DESCRIPTION Lactulose is a synthetic disaccharide in solution form for oral or rectal administration. Each 15 mL of lactulose solution, USP contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose, and 0.1 g or less of fructose). Lactulose is a colonic acidifier for treatment and prevention of portal-systemic encephalopathy. The chemical name for lactulose is 4-O- β -D-galactopyranosyl-D-fructofuranose. It has the following structural formula: The molecular weight is 342.30. It is freely soluble in water. 867ede97-figure-01"],"precautions":["PRECAUTIONS General Since lactulose solution contains galactose (less than 1.6 g/15 mL) and lactose (less than 1.2 g/15 mL) it should be used with caution in diabetics. In the overall management of portal-systemic encephalopathy, it should be recognized that there is serious underlying liver disease with complications such as electrolyte disturbance (e.g., hypokalemia) for which other specific therapy may be required. Infants receiving lactulose may develop hyponatremia and dehydration. Drug Interactions There have been conflicting reports about the concomitant use of neomycin and lactulose solution. Theoretically, the elimination of certain colonic bacteria by neomycin and possibly other anti-infective agents may interfere with the desired degradation of lactulose and thus prevent the acidification of colonic contents. Thus the status of the lactulose-treated patient should be closely monitored in the event of concomitant oral anti-infective therapy. Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose. Other laxatives should not be used, especially during the initial phase of therapy for portal-systemic encephalopathy, because the loose stools resulting from their use may falsely suggest that adequate lactulose dosage has been achieved. Carcinogenesis, Mutagenesis, Impairment of Fertility There are no known human data on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility. There are no known animal data on long-term potential for mutagenicity. Administration of lactulose solution in the diet of mice for 18 months in concentrations of 3 and 10 percent (v/w) did not produce any evidence of carcinogenicity. In studies of mice, rats, and rabbits, doses of lactulose solution up to 6 or 12 mL/kg/day produced no deleterious effects in breeding, conception, or parturition. Pregnancy Teratogenic Effects Pregnancy category B . Reproduction studies have been performed in mice, rats, and rabbits at doses up to 2 or 4 times the usual human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to lactulose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lactulose solution is administered to a nursing woman. Pediatric Use Very little information on the use of lactulose in pediatric patients has been recorded (see DOSAGE AND ADMINISTRATION )."],"how_supplied":["HOW SUPPLIED Lactulose Solution USP, 10 g/15 ml, is a natural colored and an unflavored solution supplied in one pint (473 ml) bottles. Lactulose solution, USP contains lactulose 670 mg/mL (10 g/15 mL). Store between 36° to 86°F (2° to 30°C). Do not freeze. Under recommended storage conditions, a normal darkening of color may occur. Such darkening is characteristic of sugar solutions and does not affect therapeutic action. Prolonged exposure to temperatures above 86°F (30°C) or to direct light may cause extreme darkening and turbidity which may be pharmaceutically objectionable. If this condition develops, do not use. Prolonged exposure to freezing temperatures may cause change to a semi-solid, too viscous to pour. Viscosity will return to normal upon warming to room temperature. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure. Manufactured and packaged by: Fresenius Kabi Austria GmbH Estermannstraße 17 4020 Linz, Austria Manufactured for: Teva Pharmaceuticals Parsippany, NJ 07054 USA Revised – June 2022"],"pediatric_use":["Pediatric Use Very little information on the use of lactulose in pediatric patients has been recorded (see DOSAGE AND ADMINISTRATION )."],"effective_time":"20220601","nursing_mothers":["Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lactulose solution is administered to a nursing woman."],"adverse_reactions":["ADVERSE REACTIONS Precise frequency data are not available. Lactulose may produce gaseous distention with flatulence or belching and abdominal discomfort such as cramping in about 20% of patients. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia, and hypernatremia. Nausea and vomiting have been reported. To report SUSPECTED ADVERSE EVENTS, contact the FDA at 1-800-FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions."],"contraindications":["CONTRAINDICATIONS Since lactulose solution contains galactose (less than 1.6 g/15 mL), it is contraindicated in patients who require a low galactose diet."],"drug_interactions":["Drug Interactions There have been conflicting reports about the concomitant use of neomycin and lactulose solution. Theoretically, the elimination of certain colonic bacteria by neomycin and possibly other anti-infective agents may interfere with the desired degradation of lactulose and thus prevent the acidification of colonic contents. Thus the status of the lactulose-treated patient should be closely monitored in the event of concomitant oral anti-infective therapy. Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose. Other laxatives should not be used, especially during the initial phase of therapy for portal-systemic encephalopathy, because the loose stools resulting from their use may falsely suggest that adequate lactulose dosage has been achieved."],"general_precautions":["General Since lactulose solution contains galactose (less than 1.6 g/15 mL) and lactose (less than 1.2 g/15 mL) it should be used with caution in diabetics. In the overall management of portal-systemic encephalopathy, it should be recognized that there is serious underlying liver disease with complications such as electrolyte disturbance (e.g., hypokalemia) for which other specific therapy may be required. Infants receiving lactulose may develop hyponatremia and dehydration."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Lactulose causes a decrease in blood ammonia concentration and reduces the degree of portalsystemic encephalopathy. These actions are considered to be results of the following: Bacterial degradation of lactulose in the colon acidifies the colonic contents. This acidification of colonic contents results in the retention of ammonia in the colon as the ammonium ion. Since the colonic contents are then more acid than the blood, ammonia can be expected to migrate from the blood into the colon to form the ammonium ion. The acid colonic contents convert NH 3 to the ammonium ion (NH 4 )+, trapping it and preventing its absorption. The laxative action of the metabolites of lactulose then expels the trapped ammonium ion from the colon. Experimental data indicate that lactulose is poorly absorbed. Lactulose given orally to man and experimental animals resulted in only small amounts reaching the blood. Urinary excretion has been determined to be 3% or less and is essentially complete within 24 hours. When incubated with extracts of human small intestinal mucosa, lactulose was not hydrolyzed during a 24-hour period and did not inhibit the activity of these extracts on lactose. Lactulose reaches the colon essentially unchanged. There it is metabolized by bacteria with the formation of low molecular weight acids that acidify the colon contents."],"indications_and_usage":["INDICATIONS AND USAGE For the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25 to 50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients' protein tolerance is also frequently observed with lactulose therapy. In the treatment of chronic portal-systemic encephalopathy, Lactulose has been given for over 2 years in controlled studies."],"spl_unclassified_section":["Rx Only"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Oral Adult: The usual adult, oral dosage is 2 to 3 tablespoonfuls (30 to 45 ml, containing 20 g to 30 g of lactulose) three or four times daily. The dosage may be adjusted every day or two to produce 2 or 3 soft stools daily. Hourly doses of 30 to 45 ml of Lactulose may be used to induce the rapid laxation indicated in the initial phase of the therapy of portal-systemic encephalopathy. When the laxative effect has been achieved, the dose of lactulose may then be reduced to the recommended daily dose. Improvement in the patient's condition may occur within 24 hours but may not begin before 48 hours or even later. Continuous long-term therapy is indicated to lessen the severity and prevent the recurrence of portal-systemic encephalopathy. The dose of lactulose for this purpose is the same as the recommended daily dose. Pediatric Very little information on the use of lactulose in young children and adolescents has been recorded. As with adults, the subjective goal in proper treatment is to produce 2 to 3 soft stools daily. On the basis of information available, the recommended initial daily oral dose in infants is 2.5 to 10 ml in divided doses. For older children and adolescents, the total daily dose is 40 to 90 ml. If the initial dose causes diarrhea, the dose should be reduced immediately. If diarrhea persists, lactulose should be discontinued. Rectal When the adult patient is in the impending coma or coma stage of portal-systemic encephalopathy and the danger of aspiration exists, or when the necessary endoscopic or intubation procedures physically interfere with the administration of the recommended oral doses, lactulose solution may be given as a retention enema via a rectal balloon catheter. Cleansing enemas containing soapsuds or other alkaline agents should not be used. Three hundred ml of lactulose solution should be mixed with 700 mL of water or physiologic saline and retained for 30 to 60 minutes. Lactulose enema may be repeated every 4 to 6 hours. If the enema is inadvertently evacuated too promptly, it may be repeated immediately. The goal of treatment is reversal of the coma stage in order that the patient may be able to take oral medication. Reversal of coma may take place within 2 hours of the first enema in some patients. Lactulose, given orally in the recommended doses, should be started before Lactulose by enema is stopped entirely."],"spl_product_data_elements":["Enulose Lactulose LACTULOSE LACTULOSE GALACTOSE LACTOSE, UNSPECIFIED FORM FRUCTOSE"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 45963-438-64 Enulose (Lactulose Solution, USP) For Oral or Rectal Administration Rx only One Pint (473 mL) image"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility There are no known human data on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility. There are no known animal data on long-term potential for mutagenicity. Administration of lactulose solution in the diet of mice for 18 months in concentrations of 3 and 10 percent (v/w) did not produce any evidence of carcinogenicity. In studies of mice, rats, and rabbits, doses of lactulose solution up to 6 or 12 mL/kg/day produced no deleterious effects in breeding, conception, or parturition."]},"tags":[{"label":"Osmotic Laxative","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A06AD11","category":"atc"},{"label":"Oral","category":"route"},{"label":"Powder","category":"form"},{"label":"Solution","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Constipation","category":"indication"},{"label":"Hepatic encephalopathy","category":"indication"},{"label":"Hyperammonemia","category":"indication"},{"label":"Sanwa Kagaku Kenkyusho Co., Ltd.","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Gastrointestinal Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"2526 reports"},{"date":"","signal":"CONSTIPATION","source":"FDA FAERS","actionTaken":"2501 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"2251 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"2048 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"2031 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"1941 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"1913 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1900 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"1713 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"1690 reports"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"reported","severity":"unknown"},{"effect":"Diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal Distension","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal Pain","drugRate":"reported","severity":"unknown"},{"effect":"Flatulence","drugRate":"reported","severity":"unknown"},{"effect":"Vomiting","drugRate":"reported","severity":"unknown"},{"effect":"Dizziness","drugRate":"reported","severity":"unknown"},{"effect":"Headache","drugRate":"reported","severity":"unknown"},{"effect":"Fatigue","drugRate":"reported","severity":"unknown"},{"effect":"Asthenia","drugRate":"reported","severity":"unknown"},{"effect":"Anorexia","drugRate":"reported","severity":"unknown"},{"effect":"Dehydration","drugRate":"reported","severity":"unknown"},{"effect":"Hypokalemia","drugRate":"reported","severity":"unknown"},{"effect":"Electrolyte Imbalance","drugRate":"reported","severity":"unknown"},{"effect":"Metabolic Acidosis","drugRate":"reported","severity":"unknown"},{"effect":"Hypophosphatemia","drugRate":"reported","severity":"unknown"},{"effect":"Hypomagnesemia","drugRate":"reported","severity":"unknown"},{"effect":"Hypocalcemia","drugRate":"reported","severity":"unknown"},{"effect":"Hypokalemic Alkalosis","drugRate":"reported","severity":"unknown"},{"effect":"Hypophosphatemic Nephropathy","drugRate":"reported","severity":"unknown"},{"effect":"Metabolic Alkalosis","drugRate":"reported","severity":"unknown"}],"contraindications":["Appendicitis","Diabetes mellitus","Galactosemia","Gastrointestinal obstruction"],"specialPopulations":{"Pregnancy":"Reproduction studies have been performed in mice, rats, and rabbits at doses up to or times the usual human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to lactulose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Sanwa Kagaku Kenkyusho Co., Ltd.","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0117/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$4","description":"LACTULOSE 10 GM/15 ML SOLUTION","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LACTULOSE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:21:04.759389+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Lactulose","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:21:11.769901+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:21:10.366296+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:21:03.710217+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LACTULOSE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:21:10.683145+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:21:02.713318+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:21:02.713352+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:21:02.713357+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:21:12.230543+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL296306/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:21:11.423929+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA090502","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:21:02.713361+00:00"}},"allNames":"cephulac","offLabel":[],"synonyms":["lactulose","bifiteral","cephulac","D-Lactulose","isolactose","lactulose hydrate"],"timeline":[{"date":"1976-03-25","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"1988-08-15","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 2 manufacturers approved"},{"date":"2018-09-21","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Sanwa Kagaku Kenkyusho Co., Ltd.)"}],"approvals":[{"date":"1976-03-25","orphan":false,"company":"","regulator":"FDA"},{"date":"2018-09-21","orphan":false,"company":"Sanwa Kagaku Kenkyusho Co., Ltd.","regulator":"PMDA"}],"brandName":"Cephulac","ecosystem":[{"indication":"Constipation","otherDrugs":[{"name":"bisacodyl","slug":"bisacodyl","company":"Braintree"},{"name":"cholic acid","slug":"cholic-acid","company":"Rtrx"},{"name":"docusate sodium","slug":"docusate-sodium","company":""},{"name":"glycerol","slug":"glycerol","company":"B Braun"}],"globalPrevalence":1120000000},{"indication":"Hepatic encephalopathy","otherDrugs":[{"name":"neomycin","slug":"neomycin","company":"Monarch Pharms"},{"name":"rifaximin","slug":"rifaximin","company":"Salix Pharms"}],"globalPrevalence":null},{"indication":"Hyperammonemia","otherDrugs":[{"name":"benzoic acid","slug":"benzoic-acid","company":""},{"name":"phenylacetic acid","slug":"phenylacetic-acid","company":"B Braun"},{"name":"sodium benzoate","slug":"sodium-benzoate","company":""}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","moaClass":"Acidifying Activity","modality":"Small Molecule","drugClass":"Osmotic Laxative [EPC]","explanation":"","oneSentence":"","technicalDetail":"Cephulac is a disaccharide composed of fructose and galactose molecules that are not digestible by intestinal enzymes, allowing them to reach the colon intact. In the colon, these molecules are fermented by bacteria, producing short-chain fatty acids and drawing water into the intestinal lumen, resulting in a soft and bulky stool."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Lactulose","title":"Lactulose","extract":"Lactulose is a non-absorbable sugar used in the treatment of constipation and hepatic encephalopathy. It is administered orally for constipation, and either orally or rectally for hepatic encephalopathy. It generally begins working after 8–12 hours, but may take up to 2 days to improve constipation.","wiki_society_and_culture":"==Society and culture==\n\n===Name===\nLactulose  is its international nonproprietary name (INN). It is sold under various brand names.\n\n===Availability===\nLactulose is available as a generic medication. It is available without prescription in most countries, but a prescription is required in the United States, Philippines, and Austria."},"commercial":{"launchDate":"1976","_launchSource":"DrugCentral (FDA 1976-03-25, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1536","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LACTULOSE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LACTULOSE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Lactulose","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:03:38.467911","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:21:14.645390+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"magnesium carbonate","drugSlug":"magnesium-carbonate","fdaApproval":"1990-10-02","relationship":"same-class"},{"drugName":"magnesium oxide","drugSlug":"magnesium-oxide","fdaApproval":"1982-06-22","relationship":"same-class"},{"drugName":"magnesium sulfate","drugSlug":"magnesium-sulfate","fdaApproval":"1981-10-06","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"lactitol","drugSlug":"lactitol","fdaApproval":"2020-02-12","patentExpiry":"May 12, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"sodium sulfate","drugSlug":"sodium-sulfate","fdaApproval":"1986-04-30","relationship":"same-class"},{"drugName":"macrogol","drugSlug":"macrogol","fdaApproval":"1984-07-13","relationship":"same-class"},{"drugName":"mannitol","drugSlug":"mannitol","fdaApproval":"1964-06-08","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sodium phosphate","drugSlug":"sodium-phosphate","fdaApproval":"1983-05-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"sorbitol","drugSlug":"sorbitol","fdaApproval":"1971-08-20","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"magnesium citrate","drugSlug":"magnesium-citrate","fdaApproval":"","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"lactulose","indications":{"approved":[{"name":"Constipation","source":"DrugCentral","snomedId":14760008,"regulator":"FDA","eligibility":"Adults and children 3 months of age and older","usPrevalence":null,"globalPrevalence":1120000000,"prevalenceMethod":"curated","prevalenceSource":"Am J Gastroenterol, 2011 (PMID:21606976)"},{"name":"Hepatic encephalopathy","source":"DrugCentral","snomedId":13920009,"regulator":"FDA","eligibility":"Adults and children 3 months of age and older"},{"name":"Hyperammonemia","source":"DrugCentral","snomedId":9360008,"regulator":"FDA","eligibility":"Adults and children 3 months of age and older"}],"offLabel":[],"pipeline":[]},"currentOwner":"Sanofi Aventis Us","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"magnesium-carbonate","brandName":"magnesium carbonate","genericName":"magnesium carbonate","approvalYear":"1990","relationship":"same-class"},{"drugId":"magnesium-oxide","brandName":"magnesium oxide","genericName":"magnesium oxide","approvalYear":"1982","relationship":"same-class"},{"drugId":"magnesium-sulfate","brandName":"magnesium sulfate","genericName":"magnesium sulfate","approvalYear":"1981","relationship":"same-class"},{"drugId":"lactitol","brandName":"lactitol","genericName":"lactitol","approvalYear":"2020","relationship":"same-class"},{"drugId":"sodium-sulfate","brandName":"sodium sulfate","genericName":"sodium sulfate","approvalYear":"1986","relationship":"same-class"},{"drugId":"macrogol","brandName":"macrogol","genericName":"macrogol","approvalYear":"1984","relationship":"same-class"},{"drugId":"mannitol","brandName":"mannitol","genericName":"mannitol","approvalYear":"1964","relationship":"same-class"},{"drugId":"sodium-phosphate","brandName":"sodium phosphate","genericName":"sodium phosphate","approvalYear":"1983","relationship":"same-class"},{"drugId":"sorbitol","brandName":"sorbitol","genericName":"sorbitol","approvalYear":"1971","relationship":"same-class"},{"drugId":"magnesium-citrate","brandName":"magnesium citrate","genericName":"magnesium citrate","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07501078","phase":"PHASE2","title":"Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation","status":"NOT_YET_RECRUITING","sponsor":"Muhammad N Aslam, MD","startDate":"2026-05","conditions":["Ulcerative Colitis","Ileal Pouch"],"enrollment":52,"completionDate":"2029-05"},{"nctId":"NCT07178366","phase":"NA","title":"Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-05-10","conditions":["Acute-on-Chronic Liver Failure (ACLF)"],"enrollment":56,"completionDate":"2027-10"},{"nctId":"NCT07479238","phase":"","title":"Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-03-15","conditions":["SIBO","Pancreatic Insufficiency","Chronic Pancreatitis","Pancreatic Surgey"],"enrollment":100,"completionDate":"2028-01-26"},{"nctId":"NCT07454408","phase":"PHASE1,PHASE2","title":"Evaluation of the Outcome of Fecal Microbiota Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2026-03-07","conditions":["Hepatic Encephalopathy","Fecal Microbiota Transplantation","TIPS"],"enrollment":40,"completionDate":"2028-06-30"},{"nctId":"NCT07354100","phase":"PHASE1,PHASE2","title":"Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-12-15","conditions":["Cancer"],"enrollment":55,"completionDate":"2029-04-13"},{"nctId":"NCT07140120","phase":"","title":"LiveSMART Trial to Prevent Falls in Patients With Cirrhosis - Supplementary Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan","startDate":"2023-06-13","conditions":["Cirrhosis, Liver","Portal Hypertension"],"enrollment":52,"completionDate":"2026-06"},{"nctId":"NCT07422948","phase":"NA","title":"Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-05","conditions":["Acute on Chronic Liver Failure"],"enrollment":113,"completionDate":"2027-08-30"},{"nctId":"NCT03898856","phase":"PHASE4","title":"Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2019-04-01","conditions":["Chronic Diarrhea of Unknown Origin"],"enrollment":93,"completionDate":"2025-01-30"},{"nctId":"NCT06768827","phase":"NA","title":"New Mechanisms of Obesity","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-11-13","conditions":["Obesity and Overweight","Insulin Resistance","Obesity and Obesity-related Medical Conditions"],"enrollment":55,"completionDate":"2030-03-31"},{"nctId":"NCT07360535","phase":"PHASE2","title":"Effect of Probiotic on Gut Microbiota in Young Children With Functional Constipation","status":"RECRUITING","sponsor":"Min-Tze LIONG","startDate":"2020-06-10","conditions":["Functional Constipation in Children"],"enrollment":150,"completionDate":"2026-02-28"},{"nctId":"NCT05849012","phase":"NA","title":"A Pilot Study Examining Low Sulfur Diet as Treatment for Persistent Symptoms in Quiescent Crohn's Disease","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2023-12-12","conditions":["Crohn's Disease in Remission"],"enrollment":20,"completionDate":"2027-04-30"},{"nctId":"NCT07337707","phase":"NA","title":"New Microbiota-endocrine Axis in Fructose Malabsorption-caused Visceral Hypersensitivity in Irritable Bowel Syndrome.","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-02","conditions":["Irritable Bowel Syndrome (IBS)"],"enrollment":60,"completionDate":"2027-08"},{"nctId":"NCT03729271","phase":"PHASE4","title":"Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2020-01-09","conditions":["Irritable Bowel Syndrome","Irritable Bowel Syndrome With Diarrhea"],"enrollment":148,"completionDate":"2026-01-01"},{"nctId":"NCT05253287","phase":"PHASE2,PHASE3","title":"Growth Hormone in Decompensated Liver Cirrhosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-02-01","conditions":["Liver Cirrhosis","Fibrosis","End Stage Liver Disease","Digestive System Disease","Physiological Effect of Drugs","Growth Hormone Treatment","Sarcopenia"],"enrollment":96,"completionDate":"2024-12-31"},{"nctId":"NCT07273734","phase":"NA","title":"UDCA to Prevent Post-TIPS Hepatic Encephalopathy","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-01-01","conditions":["Hepatic Encephalopathy (HE)","TIPS"],"enrollment":270,"completionDate":"2027-12-31"},{"nctId":"NCT06862986","phase":"NA","title":"Ear Massage Effect on Bowel Activity After Surgery","status":"COMPLETED","sponsor":"Mersin University","startDate":"2025-09-10","conditions":["Constipation","Lower Extremity Surgery"],"enrollment":40,"completionDate":"2025-12-04"},{"nctId":"NCT06123195","phase":"NA","title":"Effects of Constipation Treatment in Chronic Kidney Disease: A Pilot Feasibility Trial","status":"COMPLETED","sponsor":"University of Tennessee","startDate":"2024-02-01","conditions":["Chronic Kidney Disease","Constipation"],"enrollment":14,"completionDate":"2025-11-17"},{"nctId":"NCT06876064","phase":"","title":"National Cohort of Subjects at Risk of Developing Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-10","conditions":["Rheumatoid Arthritis (RA)"],"enrollment":150,"completionDate":"2027-12"},{"nctId":"NCT07066176","phase":"NA","title":"Establishing and Validating a Meal-provoked Intestinal Permeability Test for Nutritional and Metabolic Health Clinical Research.","status":"COMPLETED","sponsor":"Laval University","startDate":"2025-07-07","conditions":["Intestinal Permeability"],"enrollment":10,"completionDate":"2025-08-15"},{"nctId":"NCT05794555","phase":"PHASE3","title":"LiveSMART Trial to Prevent Falls in Patients With Cirrhosis","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2023-06-13","conditions":["Cirrhosis, Liver","Portal Hypertension"],"enrollment":230,"completionDate":"2025-03-07"},{"nctId":"NCT05754996","phase":"PHASE3","title":"Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-03-12","conditions":["Hepatic Encephalopathy"],"enrollment":80,"completionDate":"2025-07-29"},{"nctId":"NCT07145580","phase":"","title":"Combined Lactulose H2-breath Test With Abdominal Imaging","status":"RECRUITING","sponsor":"Klinik Arlesheim","startDate":"2025-08-01","conditions":["Food Intolerance Syndromes","Small Intestinal Bacterial Overgrowth Syndrome (SIBO)","Breath Tests"],"enrollment":500,"completionDate":"2026-12-31"},{"nctId":"NCT06483737","phase":"NA","title":"Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-06-24","conditions":["Overt Hepatic Encephalopathy"],"enrollment":174,"completionDate":"2027-06-30"},{"nctId":"NCT07131306","phase":"PHASE2","title":"National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II Trial","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2027-01","conditions":["Acute-On-Chronic Liver Failure"],"enrollment":100,"completionDate":"2031-08"},{"nctId":"NCT07075315","phase":"PHASE3","title":"National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2028-01","conditions":["Acute-On-Chronic Liver Failure"],"enrollment":100,"completionDate":"2031-12"},{"nctId":"NCT07084350","phase":"NA","title":"Combination of Lactulose and Polyethylene Glycol Electrolytes Powder (PEG-ELS) for Bowel Preparation in Type II Diabetes Mellitus Patients","status":"NOT_YET_RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-08-25","conditions":["Type II Diabetes Mellitus"],"enrollment":254,"completionDate":"2026-07-25"},{"nctId":"NCT07060222","phase":"PHASE4","title":"Intestinal Preparation in Colonoscopy: Lactulose vs Sodium Phosphate.","status":"NOT_YET_RECRUITING","sponsor":"Hospital Civil de Guadalajara","startDate":"2025-07-20","conditions":["Bowel Preparation for Colonoscopy"],"enrollment":300,"completionDate":"2025-12-31"},{"nctId":"NCT07065942","phase":"NA","title":"Effects of Lactulose on Gut Microbiota and Metabolism in Diabetic Constipated Patients","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-07-01","conditions":["Diabetes Mellitus","Constipation - Functional"],"enrollment":60,"completionDate":"2026-07-30"},{"nctId":"NCT07037394","phase":"PHASE4","title":"A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.","status":"COMPLETED","sponsor":"Qurratul Ain Jamil","startDate":"2024-12-02","conditions":["Overt Hepatic Encephalopathy"],"enrollment":252,"completionDate":"2025-04-30"},{"nctId":"NCT06543498","phase":"NA","title":"The Effect of Dietary Supplementation on Intestinal Barrier Function in IBS-D","status":"COMPLETED","sponsor":"Dr Anthony Hobson","startDate":"2024-08-01","conditions":["Irritable Bowel Syndrome With Diarrhea"],"enrollment":32,"completionDate":"2025-01-13"},{"nctId":"NCT00001337","phase":"PHASE2","title":"Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1993-05-08","conditions":["Diffuse Large B-Cell Lymphoma (DLBCL)","Primary Mediastinal Large B-cell Lymphoma","Burkitt Lymphoma","Anaplastic Large-Cell Lymphoma","Gray Zone Lymphoma"],"enrollment":348,"completionDate":"2024-05-24"},{"nctId":"NCT06538077","phase":"PHASE4","title":"BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2025-02-01","conditions":["Hepatic Encephalopathy","Decompensated Cirrhosis","Minimal Hepatic Encephalopathy"],"enrollment":336,"completionDate":"2027-08"},{"nctId":"NCT05700695","phase":"PHASE1","title":"Intravenous BCAA for HE in ACLF (BCAA-HE-ACLF)","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2023-01-17","conditions":["Hepatic Encephalopathy","Acute-On-Chronic Liver Failure"],"enrollment":114,"completionDate":"2025-06-05"},{"nctId":"NCT07002827","phase":"NA","title":"Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-05-30","conditions":["Decompensated Liver Cirrhosis"],"enrollment":60,"completionDate":"2026-04-30"},{"nctId":"NCT06995586","phase":"NA","title":"Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","status":"NOT_YET_RECRUITING","sponsor":"Nicosia General Hospital","startDate":"2025-09-01","conditions":["Cardio-pulmonary Bypass","Cardiovascular Diseases","Omega-3 Polyunsaturated Fatty Acids","Omega-3 Supplementation","Vitamin C","Supplements","Postoperative Depression","Antioxidants","Lactulose","Postoperative","Optimal Medical Therapy","CABG","Coronary Artery Bypass Grafting","Prebiotics"],"enrollment":108,"completionDate":"2028-09-01"},{"nctId":"NCT06317441","phase":"NA","title":"The Safety And Efficacy Of A Probiotic Intervention On Lactulose Hydrogen Breath Test-Positive Patients And Related Gastrointestinal Symptoms","status":"RECRUITING","sponsor":"Nimble Science Ltd.","startDate":"2024-07-20","conditions":["Small Intestinal Bacterial Overgrowth","SIBO"],"enrollment":105,"completionDate":"2026-12"},{"nctId":"NCT04705662","phase":"NA","title":"GI Effects of Iron in Healthy Volunteers","status":"COMPLETED","sponsor":"Dr Anthony Hobson","startDate":"2021-03-01","conditions":["Iron Deficiency Anemia Treatment","Microbial Colonization","Iron-deficiency","Iron Deficiency Anemia"],"enrollment":48,"completionDate":"2022-06-30"},{"nctId":"NCT04578886","phase":"PHASE3","title":"The Effect of Guanfacine on Delirium in Critically Ill Patients","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2020-11-23","conditions":["Delirium"],"enrollment":100,"completionDate":"2023-04-01"},{"nctId":"NCT05054361","phase":"","title":"Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2022-01-01","conditions":["Type1diabetes"],"enrollment":180,"completionDate":"2027-08-14"},{"nctId":"NCT06835361","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis","status":"RECRUITING","sponsor":"AVVA Pharmaceuticals Ltd.","startDate":"2024-02-29","conditions":["Candidal Vulvovaginitis (ICD-10 Code: B37.3)","Vulvovaginal Candidiasis (VVC)"],"enrollment":264,"completionDate":"2025-11-30"},{"nctId":"NCT05604274","phase":"","title":"Longitudinal Monitoring of Stool Characteristics","status":"COMPLETED","sponsor":"Hunter Holmes Mcguire Veteran Affairs Medical Center","startDate":"2022-10-28","conditions":["Cirrhosis, Liver"],"enrollment":60,"completionDate":"2023-10-28"},{"nctId":"NCT06248736","phase":"","title":"Description of Lactulose Administration by Balloon Rectal Tube in Severe Hepatic Encephalopathy","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2022-06-07","conditions":["Hepatic Encephalopathy"],"enrollment":25,"completionDate":"2024-08-27"},{"nctId":"NCT06808009","phase":"NA","title":"Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Related Outcomes (GOAL Trial)","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-02-05","conditions":["Acute on Chronic Liver Failure"],"enrollment":90,"completionDate":"2026-02-28"},{"nctId":"NCT06802042","phase":"NA","title":"Effect of Lactobacillus DSM17938+ on Functional Constipation and Intestinal Flora in Pregnant Women","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-01-09","conditions":["Functional Constipation (FC)"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT04073290","phase":"PHASE4","title":"Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2020-01-21","conditions":["Hepatic Encephalopathy","Cirrhosis, Liver","Portal Hypertension","Liver Diseases","Pathological Processes"],"enrollment":238,"completionDate":"2026-12-31"},{"nctId":"NCT06748638","phase":"PHASE4","title":"Clinical Study on the Application of Lactulose Combined with Linaclotide in Bowel Preparation for Colonoscopy","status":"ENROLLING_BY_INVITATION","sponsor":"Haifeng Lan","startDate":"2024-09-01","conditions":["Lactulose","Bowel Preparation"],"enrollment":444,"completionDate":"2025-10-01"},{"nctId":"NCT06738550","phase":"NA","title":"Effect of Agave Inulin on Constipation and Quality of Life in Peritoneal Dialysis Patients.","status":"ENROLLING_BY_INVITATION","sponsor":"NIN Institute","startDate":"2023-03-01","conditions":["Constipation","Peritoneal Dialysis (PD)","CKD","Quality of Life (QOL)"],"enrollment":45,"completionDate":"2025-08-31"},{"nctId":"NCT06666556","phase":"PHASE4","title":"Bowel Preparation in Colonoscopy: Lactulose Vs Polyethyleneglycol, Randomized Double-blind Comparative Clinical Trial, Multicenter Study.","status":"RECRUITING","sponsor":"Hospital Civil de Guadalajara","startDate":"2024-07-20","conditions":["Colorectal Cancer Screening"],"enrollment":300,"completionDate":"2025-08-01"},{"nctId":"NCT03384784","phase":"PHASE2","title":"Effect of Galantamine on Inflammation and Cognition","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-10-30","conditions":["HIV Associated Cognitive Motor Complex"],"enrollment":63,"completionDate":"2022-05-31"},{"nctId":"NCT03148002","phase":"PHASE4","title":"Peritoneal Dialysis Pilot Study: Evaluating Polyethylene Glycol (PEG) for Constipation","status":"COMPLETED","sponsor":"Nova Scotia Health Authority","startDate":"2017-07-07","conditions":["Constipation","Peritoneal Dialysis Complication"],"enrollment":25,"completionDate":"2018-06-05"},{"nctId":"NCT06411314","phase":"PHASE3","title":"Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis","status":"COMPLETED","sponsor":"Avva Rus, JSC","startDate":"2022-12-29","conditions":["Vulvovaginal Candidiasis, Genital"],"enrollment":218,"completionDate":"2023-09-22"},{"nctId":"NCT06368895","phase":"PHASE1","title":"Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-04-07","conditions":["Hepatic Encephalopathy","Dysbiosis"],"enrollment":60,"completionDate":"2025-06"},{"nctId":"NCT06328088","phase":"","title":"Vegetarian Versus Non Vegetarian Based Diet in the Recurrence of Hepatic Encephalopathy in Patients With Cirrhosis: An Open Label Pilot Study","status":"RECRUITING","sponsor":"Sir Ganga Ram Hospital","startDate":"2024-02-16","conditions":["Hepatic Encephalopathy"],"enrollment":40,"completionDate":"2024-10-16"},{"nctId":"NCT06282367","phase":"","title":"Bowel Preparation for Colonoscopy With Oral Lactulose","status":"COMPLETED","sponsor":"Josue Aliaga","startDate":"2021-07-01","conditions":["Colonoscopy","Colonoscopy Preparation"],"enrollment":222,"completionDate":"2023-04-01"},{"nctId":"NCT05726344","phase":"NA","title":"Lactulose vs. Polyethylene Glycol as Bowel Preparation for Colonoscopy in Adults","status":"COMPLETED","sponsor":"Hospital de Clínicas Dr. Manuel Quintela","startDate":"2023-02-10","conditions":["Lactulose","Polyethylene Glycol","Bowel Preparation","Colonoscopy","Bisacodyl"],"enrollment":150,"completionDate":"2023-12-13"},{"nctId":"NCT04667169","phase":"NA","title":"Bleeding in Laser Haemorrhoidoplasty","status":"COMPLETED","sponsor":"University of Malaya","startDate":"2015-01","conditions":["Hemorrhoids"],"enrollment":76,"completionDate":"2018-10"},{"nctId":"NCT01070212","phase":"NA","title":"Effects of Gum Chewing on Appetite and Digestion","status":"COMPLETED","sponsor":"Purdue University","startDate":"2010-02","conditions":["The Null Hypothesis is That Food Rheology Will Have no Effect on These Indices","The Alternate Hypothesis is That Increased Mechanical Stimulation Will Result in Stronger Satiation/Satiety and Reduced Energy Intake","It is Hypothesized That the Effects of Mastication Will be Less Evident in Obese Compared to Lean Individuals"],"enrollment":60,"completionDate":"2012-01"},{"nctId":"NCT05061992","phase":"PHASE2,PHASE3","title":"A Trial to Improve Quality of Life in People With Cirrhosis","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2021-11-10","conditions":["Cirrhosis"],"enrollment":56,"completionDate":"2022-11-01"},{"nctId":"NCT01756040","phase":"PHASE1","title":"Intestinal Permeability in Preterm Infants","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2013-02-01","conditions":["Prematurity","Intestinal Permeability"],"enrollment":211,"completionDate":"2021-08-31"},{"nctId":"NCT05397158","phase":"NA","title":"Optimization of Intestinal Preparation in Older Patients","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2021-09-01","conditions":["Colonoscopy","Older Adults"],"enrollment":312,"completionDate":"2022-07-31"},{"nctId":"NCT05526404","phase":"NA","title":"Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-09-14","conditions":["Hepatic Encephalopathy"],"enrollment":50,"completionDate":"2023-07-08"},{"nctId":"NCT05878639","phase":"NA","title":"Efficacy and Safety of Lactulose for Bowel Preparation in Patients With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2023-03-28","conditions":["IBD"],"enrollment":140,"completionDate":"2023-07-01"},{"nctId":"NCT05341180","phase":"PHASE2,PHASE3","title":"Efficacy of Polyethylene Glycol vs Lactulose With Isabgol in Acute Fissure-in-Ano: PEGASIS Trial","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2022-05-27","conditions":["Anal Fissure","Constipation"],"enrollment":144,"completionDate":"2023-07-22"},{"nctId":"NCT05949411","phase":"NA","title":"Development of Non-invasive Methods to Study Gut Microbiome - Nutrition - Host Interactions","status":"UNKNOWN","sponsor":"Université Catholique de Louvain","startDate":"2023-07-01","conditions":["Healthy"],"enrollment":100,"completionDate":"2024-12-31"},{"nctId":"NCT05920213","phase":"PHASE4","title":"Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy","status":"UNKNOWN","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2023-10","conditions":["Hepatic Encephalopathy Stage 2","Hepatic Encephalopathy Stage 3","Hepatic Encephalopathy Stage 4"],"enrollment":360,"completionDate":"2024-04"},{"nctId":"NCT05934552","phase":"","title":"Assesment of Lactulose vs Lactobacillus Acidophilus Effect in CKD Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-12","conditions":["CKD"],"enrollment":150,"completionDate":"2024-12"},{"nctId":"NCT05862883","phase":"PHASE2","title":"Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, ARVI","status":"COMPLETED","sponsor":"Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan","startDate":"2021-06-01","conditions":["COVID-19 Respiratory Infection"],"enrollment":301,"completionDate":"2022-07-01"},{"nctId":"NCT05859919","phase":"PHASE2","title":"Conducting Clinical Trials of the Medicine \"Rutan Tablets 0.1g\" No. 10 in the Complex Therapy of COVID-19","status":"COMPLETED","sponsor":"Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan","startDate":"2020-10-12","conditions":["Patients With COVID-19"],"enrollment":57,"completionDate":"2021-09-30"},{"nctId":"NCT05854043","phase":"NA","title":"Modified Enhanced Recovery After Oblique Lateral Interbody Fusion Surgery","status":"UNKNOWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-04-01","conditions":["Lumbar Spondylosis","Lumbar Spinal Stenosis","Lumbar Disc Herniation"],"enrollment":96,"completionDate":"2025-04-01"},{"nctId":"NCT03420144","phase":"PHASE2,PHASE3","title":"Growth Hormone Therapy in Liver Cirrhosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2018-01-15","conditions":["Cirrhosis, Liver"],"enrollment":76,"completionDate":"2020-06-30"},{"nctId":"NCT04436601","phase":"PHASE4","title":"Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Cirrhosis;(PEGHE Trial)","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2020-03-09","conditions":["Hepatic Encephalopathy"],"enrollment":102,"completionDate":"2023-12-30"},{"nctId":"NCT03515044","phase":"PHASE2","title":"Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2018-09-13","conditions":["Overt Hepatic Encephalopathy"],"enrollment":71,"completionDate":"2020-03-12"},{"nctId":"NCT05788627","phase":"PHASE4","title":"Effectiveness of Oral Lactulose Versus Lactulose Enema in Hepatic Encephalopathy","status":"UNKNOWN","sponsor":"Khyber Medical College, Peshawar","startDate":"2023-04","conditions":["Hepatic Encephalopathy","Chronic Liver Disease"],"enrollment":100,"completionDate":"2023-11"},{"nctId":"NCT05687409","phase":"PHASE4","title":"Synbiotics Interventions for Managing Cirrhosis and Its Complications","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2019-11-24","conditions":["Cirrhosis, Liver","Metagonimiasis"],"enrollment":120,"completionDate":"2022-10-24"},{"nctId":"NCT05076799","phase":"PHASE3","title":"Effect of Lactulose and/or Polyethylene Glycol Solution for Bowel Preparation for Colonscopy Procedures","status":"COMPLETED","sponsor":"Sichuan University","startDate":"2021-09-01","conditions":["Colonoscopy"],"enrollment":200,"completionDate":"2022-11-30"},{"nctId":"NCT04582942","phase":"NA","title":"Improved Bowel Preparation Method for Colonoscopy Based on Different Risk Stratification","status":"COMPLETED","sponsor":"Renmin Hospital of Wuhan University","startDate":"2020-08-06","conditions":["Bowel Preparation Before Colonoscopy"],"enrollment":2028,"completionDate":"2021-08-15"},{"nctId":"NCT05648318","phase":"NA","title":"Comparison of Oral Lactulose Versus Polyethylene Glycol for Bowel Preparation in Low-risk Patients","status":"COMPLETED","sponsor":"Zhang Xiaofeng,MD","startDate":"2022-01-08","conditions":["Colonic Neoplasms"],"enrollment":255,"completionDate":"2022-09-12"},{"nctId":"NCT05144295","phase":"PHASE3","title":"Lubiprostone for Functional Constipation in the Under 18 Years Patients","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-01-01","conditions":["Clinical Efficacy","Treatment Efficacy","Drug Side Effect"],"enrollment":274,"completionDate":"2022-11-01"},{"nctId":"NCT03261570","phase":"EARLY_PHASE1","title":"Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2017-07-01","conditions":["Postural Orthostatic Tachycardia Syndrome (POTS)","POTS","Orthostatic Intolerance"],"enrollment":51,"completionDate":"2022-06-01"},{"nctId":"NCT03462966","phase":"PHASE2","title":"Rifaximin on Visceral Hypersensitivity","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-07-01","conditions":["Visceral Hypersensitivity","Irritable Bowel Syndrome"],"enrollment":4,"completionDate":"2021-11-19"},{"nctId":"NCT04094558","phase":"NA","title":"Validation of the Small Intestine Microbiome Aspiration (SIMBA) Capsule","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2021-10-27","conditions":["Proof of Concept","Irritable Bowel Syndrome"],"enrollment":30,"completionDate":"2022-06-16"},{"nctId":"NCT05498714","phase":"NA","title":"Improved Bowel Cleansing Method for Colonoscopy Based on High Risk Population of Bowel Preparation","status":"UNKNOWN","sponsor":"Renmin Hospital of Wuhan University","startDate":"2022-07-18","conditions":["Bowel Preparation Before Colonoscopy"],"enrollment":150,"completionDate":"2023-06-30"},{"nctId":"NCT04238416","phase":"PHASE1","title":"Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2019-11-01","conditions":["Hepatic Encephalopathy","Acute-On-Chronic Liver Failure"],"enrollment":70,"completionDate":"2021-12-30"},{"nctId":"NCT04205045","phase":"","title":"Identification of Physiological Biomarkers of Gastro-intestinal Discomforts Induced by Milk Consumption","status":"COMPLETED","sponsor":"Paola Vitaglione","startDate":"2018-10-01","conditions":["Healthy Subjects"],"enrollment":40,"completionDate":"2020-01-24"},{"nctId":"NCT05428072","phase":"EARLY_PHASE1","title":"Alcohol, Gut Leakiness, & Liver Disease","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2003-01","conditions":["Alcoholic Liver Disease"],"enrollment":195,"completionDate":"2015-03"},{"nctId":"NCT03962998","phase":"EARLY_PHASE1","title":"Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability","status":"COMPLETED","sponsor":"MediBeacon","startDate":"2019-10-27","conditions":["Crohn Disease"],"enrollment":22,"completionDate":"2021-10-05"},{"nctId":"NCT03577938","phase":"NA","title":"Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment","status":"COMPLETED","sponsor":"Beijing 302 Hospital","startDate":"2019-01-10","conditions":["Acute on Chronic Liver Failure","Traditional Chinese Medicine","Hepatitis B"],"enrollment":516,"completionDate":"2021-06-30"},{"nctId":"NCT05279586","phase":"EARLY_PHASE1","title":"Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients","status":"UNKNOWN","sponsor":"Madonna Magdy Fahmy","startDate":"2022-03","conditions":["Hepatic Encephalopathy"],"enrollment":316,"completionDate":"2023-03"},{"nctId":"NCT00748904","phase":"PHASE4","title":"Rifaximin Versus Lactulose in Renal Failure","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2008-06","conditions":["Liver Cirrhosis","Renal Failure"],"enrollment":0,"completionDate":"2009-07"},{"nctId":"NCT05229289","phase":"NA","title":"Efficacy and Safety of Fecal Microbiota Transplant for Secondary Prophylaxis of Hepatic Encephalopathy","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2022-01-31","conditions":["Hepatic Encephalopathy"],"enrollment":66,"completionDate":"2022-12-31"},{"nctId":"NCT05134584","phase":"PHASE4","title":"Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2021-01-01","conditions":["Functional Dyspepsia","Constipation-predominant Irritable Bowel Syndrome"],"enrollment":78,"completionDate":"2022-02"},{"nctId":"NCT04128462","phase":"PHASE3","title":"MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function","status":"WITHDRAWN","sponsor":"Mallinckrodt","startDate":"2021-11","conditions":["Hepatic Encephalopathy"],"enrollment":0,"completionDate":"2025-07"},{"nctId":"NCT03846843","phase":"PHASE1","title":"OCR002-SP103 - Oral Immediate Release Study","status":"COMPLETED","sponsor":"Ocera Therapeutics, Inc.","startDate":"2016-08-15","conditions":["Cirrhosis"],"enrollment":30,"completionDate":"2017-12-31"},{"nctId":"NCT02358564","phase":"NA","title":"Gut Permeability, Sensitivity and Symptomatology","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-02","conditions":["Irritable Bowel Syndrome","Visceral Hypersensitivity"],"enrollment":39,"completionDate":"2021-03-11"},{"nctId":"NCT05004207","phase":"","title":"Study of Oro-cecal Transit Time in Healthy Subjects Using Scintigraphy and Lactulose Hydrogen Breath Test.","status":"UNKNOWN","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2021-07-01","conditions":["Small Bowel Disease","Motility Disorder","Irritable Bowel Syndrome"],"enrollment":50,"completionDate":"2022-01-31"},{"nctId":"NCT04821323","phase":"EARLY_PHASE1","title":"A Study Exploring the Use of Challenge Agents in Healthy Volunteers - Intervention Specific Appendix","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-10","conditions":["Healthy"],"enrollment":10,"completionDate":"2021-05-07"},{"nctId":"NCT04462211","phase":"NA","title":"Constipation Bundle/Protocol and the Effect of Adherence in the Incidence of Constipation in Critically Ill Patients","status":"COMPLETED","sponsor":"University of Chile","startDate":"2019-08-01","conditions":["Constipation","Critical Illness","Constipation Drug Induced"],"enrollment":66,"completionDate":"2020-03-01"},{"nctId":"NCT04867512","phase":"NA","title":"Botanical Blend on the Gut Microbiome and Gut-Skin-Axis in Small Intestinal Bacterial Overgrowth (SIBO)","status":"UNKNOWN","sponsor":"Integrative Skin Science and Research","startDate":"2021-04-27","conditions":["Small Intestinal Bacterial Overgrowth (SIBO)"],"enrollment":35,"completionDate":"2022-02-01"},{"nctId":"NCT04794049","phase":"NA","title":"Comparison of Oral Lactulose Versus Polyethylene Glycol for Bowel Preparation","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2021-05-01","conditions":["Colon Disease"],"enrollment":800,"completionDate":"2021-12-31"},{"nctId":"NCT04787276","phase":"NA","title":"Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Bogomolets National Medical University","startDate":"2017-01-10","conditions":["Hepatic Encephalopathy","Liver Cirrhosis","End Stage Liver DIsease"],"enrollment":42,"completionDate":"2020-03-15"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Powder, Solution","formulations":[{"form":"POWDER, FOR SOLUTION","route":"ORAL","productName":"Kristalose"},{"form":"SOLUTION","route":"ORAL","productName":"Constulose"},{"form":"SOLUTION","route":"ORAL","productName":"Enulose"},{"form":"SOLUTION","route":"ORAL","productName":"Generlac"},{"form":"SOLUTION","route":"ORAL","productName":"LACTULOSE"},{"form":"SOLUTION","route":"ORAL","productName":"Lactulose"},{"form":"SOLUTION","route":"ORAL","productName":"Lactulose Solution"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146930","MMSL":"117","NDDF":"001241","UNII":"9U7D5QH5AE","VUID":"4018617","CHEBI":"CHEBI:6359","VANDF":"4018617","INN_ID":"2137","RXNORM":"215949","UMLSCUI":"C0022957","chemblId":"CHEMBL296306","ChEMBL_ID":"CHEMBL1237068","KEGG_DRUG":"D00352","DRUGBANK_ID":"DB00581","PUBCHEM_CID":"11333","SNOMEDCT_US":"111137007","MESH_DESCRIPTOR_UI":"D007792"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Sanofi","relationship":"Current Owner"},{"period":"2018","companyName":"Sanwa Kagaku Kenkyusho Co., Ltd.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"3%"},"publicationCount":4569,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"A06AD11","allCodes":["A06AD11","A06AD61"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":24,"_genericFilersChecked":true,"genericManufacturerList":["Actavis Mid Atlantic","Alra","Ani Pharms","Apozeal Pharms","Aurobindo Pharma Ltd","Bajaj","Chartwell Rx","Cumberland Pharms","Fresenius Kabi","Hikma","Lannett Co Inc","Morton Grove","Nostrum Labs","Paco","Pai Holdings","Pai Holdings Pharm","Pharm Assoc","Pharmobedient","Roxane","Sciegen Pharms","Solvay","Taro","Teva Pharms","Vistapharm Llc"],"status":"approved","companyName":"Sanofi Aventis Us","companyId":"sanwa-kagaku-kenkyusho-co-ltd","modality":"Small molecule","firstApprovalDate":"1976","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1976-03-25T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2001-07-26T00:00:00.000Z","mah":"LANNETT CO INC","brand_name_local":null,"application_number":"ANDA075993"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-06-11T00:00:00.000Z","mah":"APOZEAL PHARMS","brand_name_local":null,"application_number":"ANDA207786"},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2018-09-21T00:00:00.000Z","mah":"Sanwa Kagaku Kenkyusho Co., Ltd.","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-11-23T00:00:00.000Z","mah":"CHARTWELL RX","brand_name_local":null,"application_number":"ANDA209517"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-08-16T00:00:00.000Z","mah":"SCIEGEN PHARMS","brand_name_local":null,"application_number":"ANDA203762"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-02-20T00:00:00.000Z","mah":"BAJAJ","brand_name_local":null,"application_number":"ANDA076645"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:21:14.645390+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}